This mixture was capable of inducing a robust interferon-gamma-producing CD8 T-cell response  and improve the therapeutic efficacy of checkpoint inhibitors in syngeneic tumor models [46], supporting the potential for a “designer mix” therapy. This evidence concerns the gene CD8A and neoplasm.